To support the hypothesis of a beneficial effect of β2-AR agonist, it has been shown that β2-AR/Gi signaling can mediate cardiac protective effects by activating cell surviving pathway [10], [47], [48], and also in vivo studies reported beneficial effects of β2-agonist therapy in HF [49]–[54]. This evidence concerns the gene GNAI1 and hydrops fetalis.